CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq:DYAX) announced today that patient treatment has begun in the Phase 3 confirmatory trial, known as EDEMA4, for its lead product candidate, DX-88 (ecallantide). DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease characterized by episodes of acute swelling and inflammation. Dyax is also initiating a Phase 2 clinical trial of DX-88 for the prevention of blood loss that occurs during on-pump cardiothoracic surgery.
